SBShubham Prashant Badadhe

Shubham Prashant Badadhe

*This is an algorithmically generated author record based on publicly available information.

Shubham Prashant Badadhe has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Greener Liquid‐Phase Synthesis of Pseudoproline Dipeptide Building Blocks in Ethanol and Water

    by Sharad M. Zade, Uddhav B. Garje, Shubham P. Badadhe, Pallavi B. Darekar, Aruna S. Shinde, Sharad N. Shelke, Pravin V. Badadhe

    A sustainable synthetic strategy for Fmoc‐protected pseudoproline dipeptides was developed to address the environmental and operational limitations of traditional solvent‐intensive methods. By utilizing ethanol as solvent during cyclisation, activated ester formation, and coupling steps, this approach eliminates the need for hazardous conventional solvents while simplifying the overall process. The protocol consistently delivers pseudoproline dipeptides in high yields and with excellent purity, demonstrating that environmentally friendly modifications can maintain strong synthetic performance. In addition to its operational simplicity and scalability, the method significantly reduces solvent‐related hazards, minimizes waste generation, and improves key green chemistry. This practical and versatile methodology provides a cleaner, more sustainable platform for the synthesis of pseudoproline‐containing intermediates relevant to peptide and pharmaceutical manufacturing.

  • Open Access

    Novel N-(4-(Chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives: Design, Synthesis, Molecular Modeling Investigation and Anticancer Activity in various cell lines

    by Pravin Vishnu Badadhe, Pradeep Balasaheb Bhise, Sandeep Balasaheb Bhise, Shubham Prashant Badadhe, Somnath Dasgupta, Ashis Nandy, Rambabu Gundla, Sona Gurska, Petr Dzubak, Marian Hajduch, et al.

    A novel series of N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives (9a–9p) were synthesized and tested for anticancer activity against multiple human cancer cell lines including K562, A549, CCRF-CEM, HCT116, HCT116 p53−/−, U2OS along with normal human fibroblast cell lines BJ and MRC-5. Significant emphasis was placed on the K562 cell line, an established model for BCR-ABL1-positive Chronic Myeloid Leukemia. Compound 9c has good potency with an IC₅₀ value of 0.22 ± 0.034 µM and selectivity (SI >100) against normal fibroblast cells such as BJ and MRC-5 cell lines. Compounds 9a (IC₅₀ = 0.82 ± 0.091 µM), followed by 9k (0.53 ± 0.04 µM), 9l (0.91 ± 0.092 µM) and 9b (0.98 ± 0.18 µM) showed good activity with favourable selectivity index (>30), however the reference drug Asciminib has remained superior with an IC50 value of 0.005 ± 0.001 µM and selectivity index value of >10000. Overall, the good activity of these compounds against K562 cells suggests a possible BCR-ABL1-related mechanism. Molecular docking studies revealed good binding affinities, with compound 9b showing the good Glide score (−8.11 kcal/mol). Although enzyme inhibition assays were not conducted but the observed selective cytotoxicity in K562 cells indicates potential modulation of BCR-ABL1 mediated signalling pathways.